ReviewEndocrine2019
Novel uses of thyroid hormones in cardiovascular conditions.
Review in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Recent Advances of Pluripotent Stem Cell-Derived Cardiomyocytes for Regenerative Medicine.Metabolites · 2025Review
- Impact of Metabolically Healthy Obesity on Cardiovascular Outcomes in Older Adults with HFpEF: Insights from a Nationwide Sample.Journal of clinical medicine · 2025Article
- Research status of subclinical hypothyroidism promoting the development and progression of cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Non-thyroidal Illness in Children with Congestive Heart FailureJournal of clinical research in pediatric endocrinology · 2024Article
- Thyroid Hormone and Heart Failure: Charting Known Pathways for Cardiac Repair/Regeneration.Biomedicines · 2023Review
- Brain nuclear receptors and cardiovascular function.Cell & bioscience · 2023Review
- Influence of Mild Thyroid Dysfunction on Outcomes after Off-Pump Coronary Artery Bypass Surgery.Journal of clinical medicine · 2022Article
- Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult.Biomedicines · 2021Article
- Prognostic role of hypothyroidism and low free-triiodothyronine levels in patients hospitalized with acute heart failure.Internal and emergency medicine · 2021Article
- Thyroid Hormones-An Underestimated Player in Dilated Cardiomyopathy?Journal of clinical medicine · 2021Review
- Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study.Diagnostics (Basel, Switzerland) · 2021Article
- Physiological Role and Use of Thyroid Hormone Metabolites - Potential Utility in COVID-19 Patients.Frontiers in endocrinology · 2021Review
- Thyroid Dysfunction and Dysmetabolic Syndrome: The Need for Enhanced Thyrovigilance Strategies.International journal of endocrinology · 2021Review
- Management of Hypothyroidism in Patients with Acute Myocardial Infarction.Medicina (Kaunas, Lithuania) · 2020Article
- Thyroid hormones and modulation of diastolic function: a promising target for heart failure with preserved ejection fraction.Therapeutic advances in endocrinology and metabolism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hormone levels are reduced in cardiovascular diseases and this phenomenon is associated with worse outcomes. It is unclear whether the changes in thyroid hormone bioavailability to the affected myocardium are beneficial or if this is a maladaptive response. Experimental studies from animal models of acute myocardial infarction (AMI) suggest that thyroid hormone treatment may be beneficial. There is limited data available on the use of thyroid hormones in patients with AMI and heart failure and this suggests that treatment to normalise thyroid hormone levels may be safe and potentially efficacious. Similarly, evidence of thyroid hormone therapy in patients undergoing cardiac surgery or during cardiac transplantation is limited. It is therefore difficult to draw any firm conclusions about benefits or risks of thyroid hormone treatment in these conditions. Large scale clinical trials of thyroid hormones in patients with cardiac conditions are required to confirm safety and evaluate efficacy. Furthermore, it needs to be elucidated which hormone to administer (thyroxine or triiodothyronine), when in the disease pathway to treat, dose of thyroid hormone to administer, and which parameters to utilise to assess safety and efficacy. Until these important questions are answered thyroid hormone therapy in cardiovascular diseases must remain within the research domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.